Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Natera (NTRA) and Agiliti (AGTI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avadel Pharmaceuticals (AVDL – Research Report), Natera (NTRA – Research Report) and Agiliti (AGTI – Research Report) with bullish sentiments.

Avadel Pharmaceuticals (AVDL)

Craig-Hallum analyst Chase Knickerbocker assigned a Buy rating to Avadel Pharmaceuticals today. The company’s shares closed last Friday at $12.62.

According to TipRanks.com, Knickerbocker is a 4-star analyst with an average return of 16.7% and a 66.0% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Fennec Pharmaceuticals, and Xeris Pharmaceuticals.

Avadel Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $23.50.

See Insiders’ Hot Stocks on TipRanks >>

Natera (NTRA)

In a report released today, Alexander Nowak from Craig-Hallum assigned a Buy rating to Natera. The company’s shares closed last Friday at $70.46, close to its 52-week high of $71.74.

According to TipRanks.com, Nowak is a 2-star analyst with an average return of 0.4% and a 41.5% success rate. Nowak covers the Healthcare sector, focusing on stocks such as NeuroOne Medical Technologies, Accelerate Diagnostics, and Tandem Diabetes Care.

Currently, the analyst consensus on Natera is a Strong Buy with an average price target of $78.38, which is a 9.6% upside from current levels. In a report issued on February 20, Raymond James also maintained a Buy rating on the stock with a $85.00 price target.

Agiliti (AGTI)

In a report released today, Matt Hewitt from Craig-Hallum assigned a Buy rating to Agiliti. The company’s shares closed last Friday at $7.64.

According to TipRanks.com, Hewitt is a 1-star analyst with an average return of -1.7% and a 45.8% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Streamline Health Solutions, Champions Oncology, and BioLife Solutions.

The the analyst consensus on Agiliti is currently a Moderate Buy rating.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AVDL:

• Avadel Pharmaceuticals initiated with a Buy at UBS
• Avadel Pharmaceuticals price target raised to $20 from $18 at Craig-Hallum
• Avadel Pharmaceuticals price target raised to $27 from $25 at Oppenheimer
• Avadel Pharmaceuticals provides update on LUMRYS launch performance
• Avadel Pharmaceuticals sees FY23 net product revenue $28M